PCM
TRVI icon

Peregrine Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Peregrine Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.29M Sell
444,310
-86,141
-16% -$1.25M 0.27% 117
2026
Q1 		$6.33M Buy
530,451
+22,766
+4% +$255K 0.23% 130
2025
Q4 		$6.36M Sell
507,685
-112,779
-18% -$1.3M 0.19% 147
2025
Q3 		$5.68M Buy
+620,464
New +$4.65M 0.17% 177

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Peregrine Capital Management's TRVI Position: Q2 2026 in Review

Peregrine Capital Management reduced its Trevi Therapeutics (TRVI) stake by 16% in Q2 2026, selling an estimated $1.25M and leaving 444,310 shares worth $8.29M. The position accounts for 0.27% of the portfolio, ranked #117.

Peregrine Capital Management first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Peregrine Capital Management held 444,310 shares of Trevi Therapeutics worth $8.29M as of Q2 2026.
  • Peregrine Capital Management sold 86,141 Trevi Therapeutics shares in Q2 2026, an estimated $1.25M.
  • Trevi Therapeutics made up 0.27% of Peregrine Capital Management's portfolio in Q2 2026, its #117 holding.
  • Peregrine Capital Management first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.